You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
眾生藥業(002317.SZ):子公司溴芬酸鈉原料藥上市申請獲批
格隆匯 10-26 22:16

格隆匯10月26日丨眾生藥業(002317.SZ)公佈,公司全資子公司廣東先強藥業有限公司(簡稱“先強藥業”)於近日收到國家藥品監督管理局核准簽發的原料藥溴芬酸鈉《化學原料藥上市申請批准通知書》。

溴芬酸鈉是一款用於眼科的非甾體抗炎藥,具有良好的抗炎活性、鎮痛作用和安全性。溴芬酸鈉滴眼液作用於眼部既能抗炎鎮痛,又可避免發生激素類藥物的副作用,隨着對溴芬酸鈉藥理機制的不斷深入,其在抗新生血管、抑制人晶狀體上皮細胞(HLECs)增殖分化、抑制視網膜神經膠質細胞增生和抑制免疫反應各方面將發揮重要的作用。

米內網中國城市公立醫院化學藥終端競爭格局數據庫顯示,溴芬酸鈉滴眼液2019至2021年銷售額分別為人民幣9520萬元,1.06億元,1.35億元。

該次溴芬酸鈉原料藥獲得《化學原料藥上市申請批准通知書》,表明該原料藥已符合國家相關藥品審評技術標準,已批准在國內製劑中使用和銷售,將豐富公司眼科原料藥產品管線,有利於公司拓展該品種的銷售。

溴芬酸鈉原料藥通過上市申請批准也是公司原料藥研發能力、生產及質量管理體系等綜合實力的體現,其上市銷售將對公司未來業績的提升產生積極的影響。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account